Event Details

Register now for the 2021 NewYorkBIO's Annual Meeting! On September 27 we will bring biotech and life science leaders together, both online and in person​, for a full-day event.



Our Annual Meeting features panels, discussion, and other speakers focused on some of the most important topics of our industry, including...

  • "The Promise, Potential, and Policy Implications of Cell and Gene Therapy"
  • "Preventing The Next Pandemic"
  • "CEO Roundtable: The Rise of Gene Therapy in NYC"
  • "How Data and Real World Evidence are Shaping the Future of Discovery and Development"
  • "The Next Wave: Financing the future of New York's Biotech Innovations"

The event will feature traditional panel discussions, networking, and a cocktail reception. Also, as our first in person event since early 2020, we are raising the bar on the agenda and including "Vision" talks - speakers who will inspire, drive our idea of what's possible, and make us think about the heights that science and innovation can achieve for human health.


Sponsorship opportunities are still available, please reach out to info@newyorkbio.org with any questions.


We look forward to seeing you in September!

Agenda

8:30 AM - 8:45 AM
Welcome Remarks
Welcome remarks from NewYorkBIO's CEO, Jennifer Hawks Bland, and President of the Board of Directors, Peter Robinson.
8:45 AM - 9 AM
Vision Talk: Raj Ratan
A TED style talk from an industry professional. Sponsored by Westchester County Economic Development
9 AM - 9:45 AM
Panel: Preventing the Next Pandemic
With the entire world impacted by the COVID19 pandemic over the past 18 months, one of the most significant talking points concerns the future: how can we work to tackle - or prevent - the n...
With the entire world impacted by the COVID19 pandemic over the past 18 months, one of the most significant talking points concerns the future: how can we work to tackle - or prevent - the next pandemic? This panel will explore the challenges we may face in the future and way that our industry, the scientific community, and our society can be prepared to respond to them. We will hear from leading scientists who have been at the forefront of the COVID19 including Florian Krammer from Mt. Sinai School of Medicine and Karl Erlandson of BARDA.

Sponsored by Regeneron Pharmaceuticals
view more
9:45 AM - 10:15 AM
Networking
A time to break, network, and discuss the content of the meeting.
10:15 AM - 10:30 AM
Vision Talk: Tanisha Carino
A TED style talk from an industry professional. Sponsored by KPMG.
10:30 AM - 11:15 AM
Panel: Promise, Potential, and Policy Implications of Cell and Gene Therapy
The advancement of cell and gene therapies over the past decade has brought initial approvals by the FDA and uptake among patient populations, taking one more step forward with the potential...
The advancement of cell and gene therapies over the past decade has brought initial approvals by the FDA and uptake among patient populations, taking one more step forward with the potential for curative therapies and hope for many patients with previously unassailable conditions. With these advancements come the challenges of complex treatment models, and policy issues surrounding patient access, pricing, and payment. This panel will explore all of the challenges and potential featuring Ginger Davis of the Sickle Cell Thalassemia Patients Network and the Honorable Alicia Hyndman, New York State Assembly Woman from the 29th District.

Sponsored by Vertex Pharmaceuticals
view more
11:15 AM - 11:30 AM
Vision Talk: Adam Taliaferro
A TED style talk from an industry professional. Sponsored by Bristol Myers Squibb.
11:30 AM - 12:30 PM
Lunch & Networking
A time for networking with attendees and to enjoy lunch.
12:30 PM - 12:45 PM
Vision Talk: Deputy Mayor Been
A TED style talk from New York City's Deputy Mayor Vicki Been. Sponsored by NYCEDC
12:45 PM - 1:30 PM
Panel: How Data and Real World Evidence is Shaping the Future of Discovery and Development
The world of data science and real world evidence has grown exponentially over the past decade, with digital health companies raising more cash than every before and larger companies all wor...
The world of data science and real world evidence has grown exponentially over the past decade, with digital health companies raising more cash than every before and larger companies all working to harness the potential of new data sources and technologies. How are these efforts impacting the way we develop medicines? Form the discovery of new targets, to more efficient clinical trials and more individually tailored therapeutic interventions, data science has touched on every aspect of the discovery and development process. This panel will cover where we stand today and the outlook for how data will continue to impact how our industry delivers new therapies to patients.

Sponsored by IBM
view more
1:30 PM - 2 PM
Networking
A time to break, network, and discussion the content of the meeting.
2 PM - 2:15 PM
Vision Talk: Luke Rosen
A TED style talk from Luke Rosen of KIF1A.org. Introduction by Michele Oshman of BIO.
2:15 PM - 3 PM
Panel: CEO Roundtable - The Rise of Gene Therapy in NYC
New York is home to several companies who are building the next wave of gene therapies, bringing the hope of curative, "one and done" interventions for a wide range of conditions. This pane...
New York is home to several companies who are building the next wave of gene therapies, bringing the hope of curative, "one and done" interventions for a wide range of conditions. This panel will feature CEOs from New York companies, including Alexandria Forbes, President and CEO of MeiraGTx and Nolan Townsend, CEO of Lexeo Therapeutics and will be moderated by Michael Glynn of Fox Rothschild. We will discuss the near and long-term hurdles and the future promise of these modalities, which have the potential to be truly disruptive breakthroughs in therapy across several indications.

Sponsored by Fox Rothschild
view more
3 PM - 3:30 PM
Networking
A time to break, network, and discuss the content of the meeting.
3:30 PM - 3:45 PM
Vision Talk: Finance
A TED style talk from an industry professional. Sponsored by JP Morgan
3:45 PM - 4:30 PM
Panel: The Next Wave: Financing the future of New York’s biotech innovations
We have lived in unprecedented times in terms of biotech financing, with each year setting a record for public offerings, the rise of SPACs as a financial vehicle, and the emergence of new f...
We have lived in unprecedented times in terms of biotech financing, with each year setting a record for public offerings, the rise of SPACs as a financial vehicle, and the emergence of new funds to fuel biotech innovation. New York has seen its own share of funds emerging across our ecosystem and this panel will discuss the future of how venture capital and the broader financial industry will continue to drive the growth of our biotech cluster.
view more
4:30 PM - 4:45 PM
Closing Remarks
Final thoughts from NewYorkBIO's CEO, Jennifer Hawks Bland.
4:45 PM - 6 PM
Reception
A cocktail reception to end the Annual Meeting. Sponsored by Conner Strong & Buckelew.

Tickets

In-Person Member

This ticket for is current NewYorkBIO members who would like to attend the meeting in person.

Member Price $495
In-Person Non-Member

This registration option is for those wanting to attend the meeting in person, who are not members of NewYorkBIO.

Standard Price $595
In-Person Patient Advocacy Member

This registration is for in-person attendees representing a patient advocacy group that is a member of NewYorkBIO

If your group is not currently a member, you can join for free on our website.

Member Price $100
In-Person Fellows Member

Attendees who are current Fellows members who would like to attend in person.

Member Price $100
Virtual Member

This registration is for members who wish to live stream the event via the NewYorkBIO website and not attend in person

Member Price $195
Virtual Non-Member

This registration is for non-members who would like to live stream the event on the NewYorkBIO website and not attend in person.

Standard Price $295
Virtual Patient Advocacy Member

This registration is for those who would like to live stream the event via the NewYorkBIO website and not attend in person. The registrant represents a patient advocacy group that is a member of NewYorkBIO

If your group is not currently a member, you can join for free on our website.

Member Price $100
Virtual Fellows Member

This registration is for current Fellows members that would like to live stream the event on the NewYorkBIO website and not attend in person.

Member Price $100

Speakers

  • DA

    Dimitris K. Agrafiotis

    Vice President, Digital, Worldwide Research, Development and Medical at Pfizer

    view more
  • Mickey Atwal (Vice President, Head of Molecular Profiling and Data Science at Regeneron Pharmaceuticals, Inc.)

    Mickey Atwal

    Vice President, Head of Molecular Profiling and Data Science at Regeneron Pharmaceuticals, Inc.

    Gurinder (Mickey) Atwal, Ph.D., is Vice President and heads the Molecular Profiling and Data Science group at Regeneron and is an adjunct associate professor at Cold Spring Harbor Laboratory. He leads the strategic development and implementation of computational tools and genomic technologies to research and cure human diseases. He has published research on machine learning and biological data science with applications in oncology, immunology, fertility, neuroscience, and virology. Recently, he has lead the bioinformatic and viral sequencing efforts at Regeneron to support the development of monoclonal antibody therapeutics against SARS-CoV-2. He received undergraduate training in both Medicine and Physics at the University of Cambridge, his Ph.D. in theoretical physics at Cornell University, and conducted post-doctoral research at Princeton University and the Institute for Advanced Study.

    view more
  • Alina Baum (Associate Director in Infectious Diseases of Regeneron Pharmaceuticals, Inc.)

    Alina Baum

    Associate Director in Infectious Diseases of Regeneron Pharmaceuticals, Inc.

    https://www.regeneron.com/

    Alina Baum is an Associate Director in Infectious Diseases at Regeneron Pharmaceuticals, where she is leading the COVID-19 spike antibody program. She received her PhD in molecular virology from the lab of Adolfo Garcia-Sastre at Mount Sinai School of Medicine and performed postdoctoral studies with Charlie Rice at Rockefeller University. Her academic career focused on studying interactions between RNA viruses and the innate immune system. In her current position at Regeneron, she is leading a virology research group developing novel therapies for viral infections, including emerging pathogens such as Ebola and SARS-CoV-2, as well as developing oncolytic viruses and therapeutic vaccines for cancer immunotherapy.

    view more
  • Deputy Mayor Vicki Been (Deputy Mayor at New York City)

    Deputy Mayor Vicki Been

    Deputy Mayor at New York City

    Deputy Mayor Vicki Been leads the de Blasio Administration’s efforts to spur recovery from the current economic crisis by investing in the City’s preparedness for future health emergencies and working to improve public health across all our neighborhoods. She oversees over 20 agencies and entities dedicated to growing and diversifying New York City's economy, building and preserving affordable housing, protecting tenants’ rights, ensuring well planned, livable and resilient neighborhoods, and fairly providing New Yorkers with wonderful parks, arts, culture, libraries and other critical neighborhood amenities. Been has extensive experience fighting to make New York a more affordable and equitable city. As HPD Commissioner from 2014 to 2017, she helped craft and implement Housing New York, the Mayor’s plan to tackle the affordability crisis and create and preserve 300,000 affordable homes by 2026. She formerly served as the Faculty Director of NYU's Furman Center for Real Estate and Urban Policy, the Weinfeld Professor of Law at the NYU School of Law, and an Affiliated Professor of Public Policy at NYU's Robert F. Wagner Graduate School of Public Service. Been graduated from Colorado State University and received her J.D. from New York University School of Law.

    view more
  • Alicyn Campbell (Head of Digital Health Oncology R&D at Astrazeneca)

    Alicyn Campbell

    Head of Digital Health Oncology R&D at Astrazeneca

    Alicyn Campbell is currently Head of Digital Health Oncology R&D at AstraZeneca, where she leads on the development of strategies designed to increase their evidence base and improve care, through intelligent use of emerging technologies.
    Alicyn has over 12 years of experience in Health Outcomes Research. Prior to joining AstraZeneca she served as the Global Head of Patient Centered Outcomes Research at Genentech/Roche. In that capacity, she was responsible for leadership in the assessment of the patient experience and consulted widely with the FDA and international regulators.
    She achieved the first ever novel FDA patient reported outcome data approved in label for Hycela and was also responsible for novel patient-reported efficacy data for Hemlibra. She is the Founder, Executive Sponsor and Co-chair of Industry PRO-CTCAE Working Group, recognised as part of the ‘Cancer Moonshot’ initiative by President Biden and is a frequent research collaborator to Friends of Cancer Research and LUNGevity.
    She has also authored several significant scientific publications and presentations, the latest of

    view more
  • Tanisha Carino, Ph.D. (Corporate Director and Non-Profit Board Member; Former Chief Corporate Affairs Officer, Alexion)

    Tanisha Carino, Ph.D.

    Corporate Director and Non-Profit Board Member; Former Chief Corporate Affairs Officer, Alexion

    Tanisha Carino, Ph.D., is a health policy expert bringing over 20 years of experience driving growth and impact across multiple healthcare leadership positions in the government, private, and non-profit sectors. She most recently served as Executive Vice President, Chief Corporate Affairs Officer of Alexion, a Fortune 500 biotechnology company focused on rare disease, which was recently acquired by AstraZeneca. Prior to Alexion, she served as Executive Director of FasterCures, a Center of the Milken Institute, a nonpartisan think tank whose mission is working with global government, philanthropic, and business leaders to accelerate treatments to patients. Previously, Dr. Carino was an executive at GlaxoSmithKline where she led the United States policy function. She also spent over ten years with Avalere Health, a premiere strategic advisory services and business intelligence firm, and worked in the U.S. Medicare program to improve access for its beneficiaries and support the development of real-world evidence in the establishment of national coverage determinations. Dr. Carino is a Fulbright Fellow and earned her Ph.D. in health policy from Johns Hopkins University. She is associate faculty at the Johns Hopkins Bloomberg School of Public Health, and she serves on the Board of Directors of Silk Road Medical, the National Health Council, the Governing Board of the Patient-Centered Outcomes Research Institute (PCORI), and the Board of Directors of Alliance for Health Policy.

    view more
  • Sue Crinnion (Managing Director with the Life Sciences Commercial Banking of J.P. Morgan)

    Sue Crinnion

    Managing Director with the Life Sciences Commercial Banking of J.P. Morgan

    Sue Crinnion is a Managing Director with the Life Sciences Commercial Banking team at J.P. Morgan. She is currently responsible for Business Development for the team nationally. She engages with a variety of Centers of Influence in the Life Sciences ecosystem to communicate J.P. Morgan’s focus on building client relationships with Life Science companies from their earliest stages and introducing the breadth of the firm as the companies progress. Sue has been involved in the buildout of this team since it was launched in 2016 and has enjoyed being a part of the growth of the Life Sciences ecosystem in New York City.
    Sue has been with J.P. Morgan her entire career with earlier coverage roles in Business Services, Apparel, and Jewelry as well as Credit Underwriting, and Business Manager for the Mid-Corporate Investment Banking Group.
    She graduated from the Peter J. Tobin College of Business at St. John’s University with a Bachelor of Science in Finance. She and her husband have four daughters. In her spare time, Sue is an avid photographer.

    view more
  • Ginger Davis (Advocate & Development Consultant at Sickle Cell Thalassemia Patients Network)

    Ginger Davis

    Advocate & Development Consultant at Sickle Cell Thalassemia Patients Network

    https://sctpn.net/

    Ginger Davis has been a life-long health and education advocate, and spokesperson for sickle cell disease. She has more than 25-years of experience in the health industry.
    Prior to starting her development and communications consultancy in 2016, she was an allied healthcare professional – working as a genetic councilor, health educator and advocate. Davis has participated in developing national health policy with organizations like NYMAC (NY-Mid Atlantic Genetics Council), and the NYS Sickle Cell Advisory Consortium. As the former Director of Outreach and Development of the Sickle Cell Thalassemia Patients Network (SCTPN) she created, implemented, and coordinated the organization’s public education program activities, in addition to implementing a diversified fundraising program.
    Through SCTPN, Ms. Davis applied her biology and naturopathic health education towards working with sixteen NYC hospitals on HRSA grants coordinating non-medical services for pediatric hematology clients and their families. Ginger is now leading SCTPN through a statewide expansion by establishing affiliate chapters.
    Ginger’s startup company UNTOLD Story LLC offers business/organizational development, marketing communications, and fundraising services to nonprofits.
    Currently, UNTOLD Story is engaged with assisting community organizations statewide and nationally go “virtual” with their annual events, and to maintain their social connections with their co-creators during the coronavirus pandemic.

    view more
  • Karl Erlandson (Interdisciplinary Scientist at BARDA)

    Karl Erlandson

    Interdisciplinary Scientist at BARDA

    Karl Erlandson, Ph.D., is an employee of U.S. Department of Health and Human Services and leads the SARS-CoV-2 Interagency Group Therapeutics team and the Operation Research Team and has focused on the rapid development and testing of viral therapeutics to emerging infectious diseases. He has worked on antiviral and antibacterial resistance at the National Institutes of Health, Harvard Medical School, and Emory University. Since joining the Influenza and Emerging Infectious Diseases Branch within the Biomedical Advanced Research and Development Authority (BARDA), Dr. Erlandson’s portfolio has included all of BARDA’s emerging infectious disease priorities. He has led several development projects from early discovery to clinical studies that rapidly developed antibody-based therapeutics and vaccines for Ebola, MERS-CoV, Zika, and SARS-CoV-2. He also founded the host-directed therapeutics group at BARDA to develop host-based therapeutics for influenza that will overcome resistance, work late in disease, and potentially work broadly against respiratory pathogens-making us more prepared for the next pandemic.

    view more
  • Jenna Foger (Senior Vice President, Science & Technology at Alexandria Real Estate Equities, Inc.)

    Jenna Foger

    Senior Vice President, Science & Technology at Alexandria Real Estate Equities, Inc.

    https://www.are.com/

    Jenna Foger provides strategic industry insights and scientific expertise to support Alexandria’s real estate operations, venture investments, thought leadership and business development initiatives. In her role, she co-manages the company’s Science & Technology team and leads its New York City-focused tenant underwriting, venture investment and other ecosystem-building activities. Prior to this role, Foger was an Associate at Windham Venture Partners where she assisted in expanding the healthcare venture fund with a particular focus on medical technology, diagnostics, and digital health investments. Before joining Windham, Foger worked as a Senior Consultant at Navigant Consulting (formerly Easton Associates), a New York City-based healthcare consulting firm that specializes in new product evaluation and strategic planning for companies across the pharmaceutical, biotechnology and medical device industries. Foger earned her Master’s in Biotechnology from Columbia University and graduated Phi Beta Kappa summa cum laude from the University of Pennsylvania with a B.A. degree in cognitive science with concentrations in neuroscience and psychology.

    view more
  • Zandy Forbes, Ph.D. (President and CEO of MeiraGTx)

    Zandy Forbes, Ph.D.

    President and CEO of MeiraGTx

    https://meiragtx.com/

    Alexandria Forbes, Ph.D. is the President and CEO of MeiraGTx (NASDAQ: MGTX). MeiraGTx is a vertically integrated gene therapy company with core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. The company is
    developing innovative gene therapy products to cost effectively treat a range of serious
    medical disorders, with clinical programs currently in the eye, salivary gland and CNS.
    Prior to founding MeiraGTx, Dr. Forbes served as Senior Vice President of Commercial Operations at
    Kadmon Holdings, Inc., a biopharmaceutical company, from September 2013 to April 2015.Before
    joining the biotech industry, she spent 10 years as a healthcare investor at Sivik Global Partners (Argus
    Partners) and Meadowvale Partners. At Sivik, Dr. Forbes was responsible for investments in
    biotechnology, specialty pharmaceuticals and diagnostics public equities and was portfolio manager of
    the Sivik Global Life Science Fund, a long-biased public markets fund investing in biotechnology
    companies globally. During her time as a biotechnology investor, Dr. Forbes covered over 300
    companies and gained expertise in biotechnology business strategies and clinical drug development as
    well as a wide range of disease areas. Particular areas of focus included HIV, HCV, diabetes, obesity,
    autoimmune disorders, cancer, Alzheimer’s disease, kidney disease and liver disease.
    Before entering the hedge fund industry, Dr. Forbes was an academic scientist studying the regulation of
    stem cell identity and different aspects of embryogeneis. She was a Human Frontiers/Howard Hughes
    postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center,
    where her research focused on cytoplasmic determinants and cell signaling pathways involved in the
    migration, establishment and maintenance of germ line stem cells in Drosophila melanogaster. Prior to
    this, Dr. Forbes was a research fellow at Duke University and at the Carnegie Institute at Johns Hopkins
    University where she studied the role of the
    hedgehog
    embryo and adult. Dr. Forbes received her Ph.D. in Molecular Genetics from Oxford University, UK and
    gene and its signaling pathway in the Drosophila
    attained a double first degree in Natural Sciences from Cambridge University, UK.
    Dr. Forbes serves on the Board of Directors of MeiraGTx, and as a Trustee and Director of the Selfridges
    Group Foundation, the European arm of the Weston Brain Institute, a charity supporting research into
    neurodegenerative diseases with the aim of speeding the time to the development of disease modifying
    treatments for these currently intractable diseases, particularly Alzheimer’s.

    view more
  • Chris Garabedian (CEO of Xontogeny)

    Chris Garabedian

    CEO of Xontogeny

    Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and launched the Perceptive Xontogeny Venture Fund in 2018 to support early stage companies seeded and incubated at Xontogeny and other ventures.

    Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005.

    Chris serves on a number of Boards of life sciences companies and speaks at industry conferences on a wide range of important issues. Chris is also on the Board of Directors of MassBio and serves as a Senior Advisor for the Boston Consulting Group.

    view more
  • Joanne Gere (Executive Director of Westchester Biotech Project)

    Joanne Gere

    Executive Director of Westchester Biotech Project

    Ms. Gere’s career has been all about bringing researchers, engineers, and data scientists together across the many silos of biomedical progress.

    By collaborating with industry, academic, government, and nonprofit institutes, Westchester Biotech Project convenes thought leaders who are building tomorrow's Science Economy through the Westchester Data Analytics Hub, Transitions Toolkit, Rare Disease Symposium, Clinical Research Roundtable, and the Consortium on Translational Research in the Microbiome.

    view more
  • Michael Glynn (Partner at Fox Rothschild LLP)

    Michael Glynn

    Partner at Fox Rothschild LLP

    Michael’s practice centers on protection, acquisition, evaluation and enforcement of intellectual property rights primarily in the pharmaceutical, biotechnology, and medical device industries. Michael has extensive experience in all areas of patent practice, including post-grant proceedings, as well as trade secret and patent litigation, patent preparation, and prosecution. Trained in microbiology and human genetics, he previously worked at Yale University School of Medicine as a laboratory supervisor at the DNA Diagnostics Laboratory. Michael uses his knowledge and training to assist clients in identifying valuable innovations for patenting, and obtaining and managing robust and enforceable patent protection in the United States and around the world. In addition, Michael works with investment firms to evaluate intellectual property issues including strength of the target company’s patents and freedom-to-operate in view of third party intellectual property. He also conducts intellectual property due diligence in the context of corporate mergers and acquisitions, technology transfer, and licensing.

    view more
  • Jennifer Hawks Bland (Chief Executive Officer at NewYorkBIO)

    Jennifer Hawks Bland

    Chief Executive Officer at NewYorkBIO

    Jennifer Hawks Bland is the Chief Executive Officer of NewYorkBIO. Prior to joining NewYorkBIO, Ms. Bland was an Executive Director in the State Government Affairs & Policy group at Merck. She has also held government affairs positions at GlaxoSmithKline and the Consumer Healthcare Products Association (CHPA), the 136-year old trade association representing manufacturers of over-the- counter medicines. Ms. Bland previously was an associate with the Jackson, MS law firm of Butler, Snow, O’Mara, Stevens, & Cannada, PLLC where she principally practiced in the area of products liability litigation. Before entering the practice of law, she worked for six years for U.S. Senator Thad Cochran (RMiss.). Ms. Bland is a member of both the District of Columbia and Mississippi Bar Associations. She also has extensive volunteer experience and is currently the PTA co-president of her child’s school and sits on the Board of the Pelham Art Center. Ms. Bland currently resides in Pelham, New York with her husband, R. Trabue Bland and their two sons.

    view more
  • Orin Herskowitz (Columbia Technology Ventures)

    Orin Herskowitz

    Columbia Technology Ventures

    Orin Herskowitz is the Senior Vice President of Intellectual Property and Tech Transfer for Columbia University, as well as Executive Director of Columbia Technology Ventures (CTV). He also is an Adjunct Professor at Columbia’s Business and Engineering Schools. He has served on boards or served as the Principle Investigator for a number of innovation and entrepreneurship-focused initiatives, including the NYC Media Lab, the PowerBridgeNY clean energy proof-of-concept center, the Columbia Coulter Translational Partnership, the Academic Venture Exchange, the NYC ACRE technology incubator, and Harlem Biospace; has been a peer reviewer for innovation and entrepreneurship awards for the National Science Foundation, the US Small Business Association, the Association of Public and Land-grant Universities; a published author on the topic of translating university-stage technology; and is a frequent speaker at technology-focused events in NYC and across the country. Orin has also been appointed by U.S. Secretary of Commerce Penny Pritzker to the National Advisory Council on Innovation and Entrepreneurship, serving a two-year term beginning in 2016. Orin received his BA from Yale and his MBA from the Wharton School of Business. Prior to joining Columbia, Orin spent 7 years at the Boston Consulting Group's New York office as a strategy consultant, and was previously an entrepreneur and a consultant to start-ups.

    view more
  • The Hon. Alicia Hyndman (Assemblywoman at New York State Assembly)

    The Hon. Alicia Hyndman

    Assemblywoman at New York State Assembly

    Alicia L. Hyndman was elected to the New York State Assembly on November 10, 2015 in the 29th AD, encompassing the neighborhoods of Laurelton, Rosedale, St. Albans, Addisleigh Park, Hollis, Springfield Gardens and Jamaica. The daughter of Caribbean immigrants, Assemblywoman Hyndman emigrated to the U.S. from London, England as a young child. She spent her formative years growing up in Hollis & South Ozone Park attending public schools, PS 34, IS 109, JHS 226 & John Adams High School.
    Prior to being elected to the State Legislature, Assemblywoman Hyndman worked closely with community stakeholders as an active member of Community Boards 12Q, and 13Q, serving as a member of the Boards Education Committees, and also as a regular participant of the Rosedale Civic Association. Additionally, Assemblywoman Hyndman served on the NYC Department of Education’s Community District Education Council 29 (CEC 29) for ten years, the last four years as President. Leading the advocacy for the 36 elementary and middle schools in the district, through collaborative leadership, she was able to bring in $30 million in capital funding for technology upgrades, facilities improvements, playground rehabilitation and other amenities to enhance the quality of education for students.
    Assemblywoman Hyndman’s professional career spans over a decade and a half with the NYS Department of Education as a Senior Professional Conduct Investigator, overseeing trade and vocational schools. She previously has held many positions in the fields of education and higher learning including but not limited to: Counselor for the Brooklyn College Talent Search Program; Director of Minority Affairs at the New York College of Osteopathic Medicine of NYIT; Assistant with the New York State Education Department Office of Higher Education. Assemblywoman Hyndman also helped create the Long Island Barber Institute which graduated hundreds of Queens residents, allowing them to obtain jobs and become entrepreneurs, and opening dozens of establishments throughout the Borough.
    As a longtime community education advocate, Assemblywoman Hyndman will focus heavily on bringing resources and information back into the community to support youth and senior services, alleviate flooding, grow small businesses, and provide access to living wage jobs and entrepreneurial opportunities. She will continue her advocacy in Albany as a tireless fighter for residents of the 29th Assembly District.
    Assemblywoman Hyndman holds a Bachelor of Arts Degree from the State University of New York at New Paltz, and a Master’s Degree in Public Administration from Framingham State College, Mass. She is a member of Delta Sigma Theta Sorority, Incorporated. She currently resides in Rosedale, Queens with her two lovely daughters Nia and Nyla.
    Assemblywoman Alicia Hyndman currently serves as Assistant Majority Leader for the NYS Assembly.

    view more
  • Alicia Irurzun-Lafitte (Partner at UCB Ventures)

    Alicia Irurzun-Lafitte

    Partner at UCB Ventures

  • Florian Krammer, Ph.D. (Professor of Vaccinology at the Department of Microbiology at Icahn School of Medicine at Mount Sinai)

    Florian Krammer, Ph.D.

    Professor of Vaccinology at the Department of Microbiology at Icahn School of Medicine at Mount Sinai

    Florian Krammer, PhD, graduated from the University of Natural Resources and Life Sciences, Vienna (Austria) in 2010. He received his postdoctoral training in the laboratory of Dr. Peter Palese at the Icahn School of Medicine at Mount Sinai, New York working on hemagglutinin stalk-based immunity and universal influenza virus vaccines. In 2014 he became an independent principal investigator and is currently Mount Sinai Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai. Dr. Krammer's work focuses on understanding the mechanisms of interactions between antibodies and viral surface glycoproteins and on translating this work into novel, broadly protective vaccines and therapeutics. The main target is influenza virus but he is also working on coronaviruses, flaviviruses, hantaviruses, filoviruses and arenaviruses. He has published more than 300 papers on these topics. Since 2019, Dr. Krammer has served as principal investigator of the Sinai-Emory Multi-Institutional Collaborative Influenza Vaccine Innovation Center (SEM-CIVIC), which develops improved seasonal and universal influenza virus vaccines that induce long-lasting protection against drifted seasonal, zoonotic and future pandemic influenza viruses.

    view more
  • Lorraine Marchand (General Manager for Life Sciences at IBM Watson Health)

    Lorraine Marchand

    General Manager for Life Sciences at IBM Watson Health

    https://www.ibm.com/watson-health

    Lorraine is General Manager for Life Sciences at IBM Watson Health where she leads the organization dedicated to improving clinical development research, showing greater treatment value, and getting treatments to patients faster with differentiated solutions. Under her leadership, Watson Health is focused on delivering time-saving processes and critical insights to help life sciences companies make informed decisions that reduce trial costs, increase trial productivity and build a robust drug commercialization strategy. Prior to joining Watson Health, she has held executive roles in Management, Operations and Business Development for Bristol-Myers Squibb, Covance, Clinilabs and Cognizant Technology Solutions. Her responsibilities have included P&L, Clinical Development Operations, Labs, Facilities, HR, Marketing and Business Development. She developed a business model to transform a specialty contract research organization into a full-service provider and executed a new operating model for a global drug development company, increasing top line and improving operating margin by 20%. Lorraine established a global capability for a pharma company, reducing drug development cycle time 30%. She drove cost cutting initiatives at a pharma that increased productivity and efficiency~ $100 million.

    view more
  • Martin Marciniak (Vice President and Head, US Medical Affairs at Chiesi)

    Martin Marciniak

    Vice President and Head, US Medical Affairs at Chiesi

  • Scott McGoohan (Senior Director, Policy and Alliance Development of Vertex Pharmaceuticals Inc.)

    Scott McGoohan

    Senior Director, Policy and Alliance Development of Vertex Pharmaceuticals Inc.

    Scott V. McGoohan, J.D. currently serves as Senior Director, Policy and Alliance Development for Vertex Pharmaceuticals and leads Vertex’s genetic therapy policy pottfolio. Prior to joining Vertex, Scott served as Director of Scientific and Regulatory Affairs at the Biotechnology Innovation Organization, where he led a broad array of activities related to the innovative biopharmaceutical industry, and served as an industry negotiator on the FDA User Fee Agreement reauthorizations. He previously held roles with the American Clinical Laboratory Association, Harvard Medical School, and Genzyme, and worked as a contract lobbyist and scientific advisor, representing pharmaceutical and device companies and their interests on Capitol Hill. Scott received his Bachelors of Science from Boston College, specializing in molecular biology, and his Juris Doctorate from the University of Wisconsin Law School.

    view more
  • Rachel McMinn (CEO of Neurogene)

    Rachel McMinn

    CEO of Neurogene

    Dr. McMinn founded Neurogene in January 2018 with the mission of providing genetic medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families. Dr. McMinn currently serves as CEO of Neurogene. Prior to this, she spent 17 years in the biotechnology industry, most recently serving as the Chief Business and Strategy Officer of Intercept Pharmaceuticals, a company dedicated to patients with serious liver disease. Dr. McMinn was also an award-winning biotechnology analyst, with 13 years of experience at firms including Bank of America Merrill Lynch, Cowen, and Piper Jaffray. She earned her doctorate from The Scripps Research Institute and was awarded a Post-Doctoral Miller Fellowship at the University of California, Berkeley.

    view more
  • AM

    Alasdair Milton

    KPMG LLP

  • Deborah Novick (Director of Entrepreneurship and Innovation at Westchester County Office of Economic Development)

    Deborah Novick

    Director of Entrepreneurship and Innovation at Westchester County Office of Economic Development

    Deborah Novick is the Director of Entrepreneurship and Innovation within the Westchester County Office of Economic Development, where she directs the Element 46 incubator program and oversees the Biosciences Accelerator program. In addition, she looks for opportunities to grow the entrepreneurial and innovation ecosystem in Westchester.
    Novick was most recently Director of the Biotechnology Incubator at New York Medical College, a position she held since late 2017. Among her responsibilities was creating a collaborative community within the incubator and recruiting new start-ups. She was also responsible for overseeing the design and physical expansion of the incubator, which doubled in size.
    Her background also includes having served as an instructor for a course on entrepreneurship at the Women’s Enterprise Development Center; co-founded a successful real estate staging firm and served as fund manager for several venture capital funds. A resident of Larchmont, Novick earned a Bachelor of Science degree from Cornell University’s College of Industrial and Labor Relations. She holds a Chartered Financial Analyst designation.

    view more
  • Michele Oshman (Vice President, External Affairs; Executive Director, Council of State Bioscience Associations at biotechnology Innovation Organization)

    Michele Oshman

    Vice President, External Affairs; Executive Director, Council of State Bioscience Associations at biotechnology Innovation Organization

    https://www.bio.org

    Michele M. Oshman is Vice President for External Affairs at the Biotechnology Innovation Organization (BIO) and serves as the Executive Director for the Council of State Bioscience Associations (CSBA).
    Ms. Oshman joined BIO in January 2020 after a successful 18-year career at Eli Lilly and Company, where she led federal advocacy outreach. She started her career as a clinical neuroscience researcher and served in multiple clinical development and corporate leadership roles. She earned a Six Sigma Black Belt in 2005 and led multiple transformational efforts across the company before joining the advocacy team in 2007.
    From 2012-2014, she served as Chair of the Biotechnology Innovation Organization Alliance Committee and held the same position with the PhRMA Alliance Development Section from 2015-2016. She chaired the Arthritis Foundation Industry Forum from 2014 - 2016, and currently co-chairs the Lupus Foundation of America and the SickCells corporate councils. As well, she serves on the corporate advisory councils for a portfolio of national advocacy organizations.
    Ms. Oshman also serves on the Board of Directors for the American Brain Coalition and Capital Clubhouse, a Washington DC community mental health agency that provides psychosocial, vocational and housing support for people struggling with severe persistent mental illnesses in the National Capital Area.
    Ms. Oshman graduated from American University with a dual degree in Political
    Science and Communications.
    companies, academic institutions, state biotechnology
    centers and related organizations across the United
    States and over 30 countries around the world. As the
    5.20.2021 revised
    BIO is the world's
    largest trade association representing biotechnology
    leader of CSBA, a confederation of state-based, non-
    profit trade organizations each governed by its own
    board of directors, she works to advance their mission
    to promote public understanding of, and advocate for
    public policies that support the responsible
    development of the bioscience industry.

    view more
  • Dennis Purcell (Founder of Aisling Capital)

    Dennis Purcell

    Founder of Aisling Capital

    Mr. Purcell is the Founder of Aisling Capital LLC. Previously, he served as Advisor and Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.
    Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.
    In the past, Mr. Purcell has served on numerous private and public healthcare company boards. He currently sits on the Boards of Real Endpoints, Summus Global, Inc., BioScience Managers Pty Ltd., and Ichnos Sciences. He sits on the Editorial Advisory Board at Life Science Leader Magazine; Member of the Board at NYBIO Association; Board Member at The University of Delaware Investment Visiting Committee as well as a member of the Biopharmaceutical Innovation Board at the University of Delaware.
    Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.

    view more
  • Angela Radcliffe (Head- Data Gov & Stewardship, Enterprise Data Governance and Data Management Certification at Bristol Myers Squibb (BMS))

    Angela Radcliffe

    Head- Data Gov & Stewardship, Enterprise Data Governance and Data Management Certification at Bristol Myers Squibb (BMS)

    Angela Radcliffe is a clinical research expert and data ethics evangelist with over two decades of experience driving transformation and organizational agility at the intersection of health, tech, and data. Angela’s work has impacted >100 global clinical research efforts across almost every therapeutic area. As an author and speaker, Angela uses her personal journey to demonstrate how inclusive research can impact the root causes of our most challenging social issues. She is committed to the pursuit of more authentic patient engagement, giving data ownership back to humans, the promotion of health and data literacy for all, and normalizing clinical research as a care option.

    view more
  • Raj Ratan

    Raj Ratan

    Rajiv (“Raj”) Ratan received his B.A. in Neuroscience (Magna Cum Laude) from Amherst College in 1981 and received the John Woodruff Simpson Fellowship in Medicine. He completed an M.D. and Ph.D. at the New York University School of Medicine where he graduated as a member of AOA in 1988. He completed his Ph.D. with Dr. Michael Shelanski (Chair of Pathology at Columbia University) and Dr. Frederick Maxfield (Chair of Biochemistry at Cornell) where he focused on novel methods to monitor calcium gradients in living cells.

    He completed an Internship in Medicine at the University of Chicago and was a Neurology resident and then Chief Resident in Neurology at Johns Hopkins (1991-1992). He was awarded the Jay Slotkin Award for excellence in research while a resident; and subsequently received the Passano Foundation Clinician Scientist Award while completing a fellowship in Neurorehabilitation and a post-doc in the Department of Neuroscience at Hopkins. In 1994, he was promoted to Assistant Professor of Neurology and Rehab Medicine at Hopkins and he started his own lab with the help of his post-doc mentor, Jay Baraban.

    In 1996, he was recruited to set up the Neuroprotection Laboratory in the Department of Neurology and Program in Neuroscience at Harvard Medical School (Harvard Institutes of Medicine and Beth Israel Hospital). He became an Associate Professor at Harvard in 1999.

    In 2002, Dr. Ratan moved to Burke to Direct the Research Institute. He was formally appointed the Winifred Masterson Burke Professor of Neurology and Neuroscience at Weill Medical College in 2004 and named an Associate Dean for the medical college in 2011.

    view more
  • Peter Robinson (VP, Government and Community Relations at University of Rochester)

    Peter Robinson

    VP, Government and Community Relations at University of Rochester

    Mr. Robinson is the Vice President for Government and Community Relations for the University. He has responsibility for the University’s role in economic development and is a member of the Finger Lakes Regional Economic Development Council. He is a voting member of the New York State Public Health & Health Planning Council, and serves as Board Chairman for NextCorps, Inc. (HTR), Excell Partners, Inc., and New YorkBIO. He is the past Chairman for Greater Rochester Enterprise (GRE). He serves on the boards of several private and public community agencies. He earned his bachelor’s degree from the City College of New York and Master’s degrees from the New School for Social Research and Columbia University.

    view more
  • Luke Rosen (Founder & Board Chair of KIF1A.ORG)

    Luke Rosen

    Founder & Board Chair of KIF1A.ORG

    https://www.kif1a.org/

    Luke Rosen and Sally Jackson founded KIF1A.ORG in 2016 following their daughter Susannah’s KIF1A diagnosis. In 2017 Luke left his career in film and television to accelerate discovery of treatment for Susannah and children like her.

    With a focus on research strategy and outcome measures, his mission is to accelerate biotech innovation and forge efficient collaborations to rapidly discover treatment for KIF1A Associated Neurological Disorder.

    Luke also serves as senior vice president of Accelerated Development and Community Engagement at Ovid Therapeutics. He is responsible for strengthening Ovid’s patient-driven approach to the rapid development of meaningful medicines. Rosen works closely with rare disease stakeholders to forge efficient collaborations powered to impact patients, expand Ovid’s research pipeline and advance clinical programs. Mr. Rosen joined Ovid to accelerate research, discovery, and development of treatments for rare, neurological, and genetic diseases. Luke sits on multiple rare disease advisory boards; and is a passionate advocate for rare disease policy, access to diagnostics and inclusive education. He holds a Bachelor of Arts in English, a Master of Science in Bioethics and is a graduate of the British Academy of Dramatic Arts at the University of Oxford.

    view more
  • Susan Rosenthal (Senior Vice President, Life Sciences & Healthcare at New York City Economic Development Corporation)

    Susan Rosenthal

    Senior Vice President, Life Sciences & Healthcare at New York City Economic Development Corporation

    https://www.edc.nyc/

    Susan Rosenthal is the Senior Vice President, Life Sciences & Healthcare at the New York City Economic Development Corporation, which recently announced a plan to double the City’s $500 million investment in life sciences to $1 billion to create jobs and establish New York City as a global leader in life sciences. Susan also recently led NYCEDC’s COVID-19 testing team, which in partnership with City Hall and NYC Health + Hospitals helped launch the Pandemic Response Lab, created a local supply chain for COVID test kits, and evaluated technologies for point of care and rapid tests to support the City’s response to COVID-19. Susan has over fifteen years of industry experience with a rich background in business development, corporate strategy, and portfolio management from her time at Pfizer and Deloitte Consulting. Her experience spans many therapeutic areas as well as across early and late stage R&D. Sue earned her MBA from NYU and her Bachelor's degree in economics from the Massachusetts Institute of Technology.

    view more
  • Ron Siggs (Senior Vice President at Magee Rehabilitation Hospital - Jefferson Health)

    Ron Siggs

    Senior Vice President at Magee Rehabilitation Hospital - Jefferson Health

    Ron Siggs has been employed at Magee Rehabilitation Hospital in Philadelphia since 1992 is responsible for fund raising, government affairs, community programs and wheelchair sports. He also is the President of the Magee Rehabilitation Hospital Foundation. He serves as the Chair of the Board of Help Hope Live, a non profit organization located in Radnor, Pennsylvania. He has a long association with the Association of Fund Raising Professionals Greater Philadelphia Chapter, including serving as a program speaker, mentor and former board member. Mr. Siggs has an undergraduate degree from the University of Washington, a Masters of Management from Penn State University and is a Certified Fund Raising Executive. He has 2 adult children and resides in West Chester, Pennsylvania with his wife Terri.

    view more
  • Adam Taliaferro (State Advocacy & Alliance Development at Bristol Myers Squibb (BMS))

    Adam Taliaferro

    State Advocacy & Alliance Development at Bristol Myers Squibb (BMS)

    https://www.bms.com

    While playing football for Penn State in a game against rival, Ohio State, Adam Taliaferro made a routine helmet-to-helmet tackle that would change the course of his life. He had broken his neck—a similar injury suffered by the late, Christopher Reeve. Given only a 3% chance of ever walking again, Adam fought insurmountable odds to not only walk, but to walk well.

    Though playing football is no longer in Adam's future, many around the nation have followed his inspirational tale of recovery leading authors, Scott Brown and Sam Carchidi, to chronicle his remarkable story in their 2001 book Miracle in the Making. Adam currently leads State Advocacy & Alliance Development for Bristol Myers Squibb and holds office as a member of the New Jersey General Assembly. Adam also has his own foundation, “The Adam Taliaferro Foundation,” that provides financial assistance to individuals affected by spinal cord injuries of which has raised over $1 million to date. Through his foundation and his passion for motivational speaking, Adam continues to provide hope for many people who may feel that there is no reason to hope at all.

    view more
  • Nolan Townsend (CEO of LEXEO Therapeutics)

    Nolan Townsend

    CEO of LEXEO Therapeutics

    https://www.lexeotx.com/

    R. Nolan Townsend joined LEXEO Therapeutics as Chief Executive Officer in January 2020. Prior to LEXEO,
    Mr. Townsend held roles as President, Pfizer Rare Disease for the North America and International regions, respectively. Mr. Townsend has over a decade of experience with Pfizer, first joining the company in Corporate Finance and subsequently in roles of increasing responsibility across Corporate Finance, Corporate Strategy, Operations, Marketing, General Management and Commercial leadership in Pfizer’s New York headquarters, Asia, Africa/Middle East and Europe. Prior to Pfizer, Mr. Townsend worked in the healthcare investment banking group at Lehman Brothers, advising healthcare companies on strategic financing transactions and mergers and acquisitions. Mr. Townsend received his Masters in Business Administration from the Harvard Business School and his Bachelor of Arts in Economics from the University of Pennsylvania.

    view more
  • Jonathan Usuka (Chief Strategy & Informatics Officer at REALM)

    Jonathan Usuka

    Chief Strategy & Informatics Officer at REALM

    Dr. Jonathan Usuka is the Chief Strategy and Informatics Officer at REALM, a healthcare company pioneering the field of integrated diagnostics, bringing together genomics, radiology, pathology, and AI for disease insights. Prior to joining REALM this year, he served as Senior Expert in Pharmaceutical and Medical Products at McKinsey & Company from 2016 to 2021, focusing on investment opportunities in informatics and real world data. From 2009 to 2015, Dr. Usuka led R&D Informatics at Celgene Corporation, contributing to adaptive clinical studies and genetic biomarkers in oncology and immunology resulting in major label expansions and new therapeutic approvals, and was the director of Bioinformatics at Roche from 2001-2009. He earned a PhD and was an NIH Fellow at Stanford School of Medicine, and an MBA in Finance from the Wharton School, University of Pennsylvania. He currently serves on the Board of Directors at the Prostate Cancer Foundation, focusing on advanced research into early detection and cure.

    view more

Venue

One Liberty Plaza

New York

If you have any questions please contact Mary Bartlett

Contact Organizer

+1 5185885898

Show on map